Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$6.25 USD
-0.07 (-1.11%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.26 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
VYGR 6.25 -0.07(-1.11%)
Will VYGR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VYGR
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
Other News for VYGR
Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected
Voyager advances Neurocrine collaboration, selects third gene therapy candidate
Get “Picky” With Stocks For September Profits
Novartis licenses gene therapy component from Voyager
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14